According to a recent LinkedIn post from Segmed, the company is partnering with Alphabet unit Verily to support secure, scalable access to real‑world, diagnostic‑grade imaging data within Verily’s AI‑native precision health platform. The post indicates that Segmed will provide de‑identified imaging and associated clinical data into Verily’s Pre Exchange and Workbench research environment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests this integration is intended to lower barriers for investigators and speed discovery in areas such as breast cancer and other precision medicine use cases. The emphasis on privacy‑first data stewardship and scientific rigor underscores Segmed’s positioning as a compliant data infrastructure provider, which could strengthen its attractiveness to large healthcare and life‑science customers.
For investors, the collaboration with Verily, an Alphabet Inc. affiliate, may be viewed as a validation of Segmed’s technology and data assets in the competitive medical imaging and real‑world data space. Association with a major ecosystem player could support future revenue opportunities through expanded usage, additional partnerships, and deeper integration into AI‑driven clinical research workflows.
At the same time, the post does not disclose financial terms, revenue models, or exclusivity, leaving uncertainty about the immediate economic impact. However, increased visibility in precision health and AI‑in‑healthcare markets could enhance Segmed’s long‑term strategic position as demand for multimodal, high‑quality data infrastructure grows across pharma, med‑tech, and research institutions.